 Shares of Mirati Therapeutics Inc. MRTX, 0.10 jumped 6.0 in premarket trading on Thursday after the company said the Food and Drug Administration granted a breakthrough therapy designation to Krazati as a treatment for colorectal cancer. The drug is already approved to treat certain kinds of non-small cell lung cancer. 